# BBH (VanEck Biotech ETF)

VanEck · Thematic ETFs · data as of Sep 11, 2026

BBH holds 24 stocks, and 39% of its weight is outside the S&P 500.

## Key facts

- BBH, already in the S&P 500: 60.7%, as of Sep 11, 2026.
- BBH, active share vs the S&P 500: 99.0%, as of Sep 11, 2026.
- BBH, top ten holdings: 72.0%, as of Sep 11, 2026.
- BBH, total return, 1 year: +36.1%, as of Sep 11, 2026.
- BBH, net assets: $396m (SEC filing, whole fund, as filed for Jun 30, 2026).
- BBH, expense ratio: 0.35% (485BPOS XBRL, Jan 27, 2026).

## BBH over each window to Sep 11, 2026

| Window | Total return | S&P 500 | Gap to S&P 500 | Gap to Nasdaq-100 |
| --- | --- | --- | --- | --- |
| 3 months | +22.3% | +3.3% | +19.0 pts | +23.1 pts |
| 6 months | +22.9% | +16.0% | +6.9 pts | +2.2 pts |
| 1 year | +36.1% | +17.5% | +18.6 pts | +13.1 pts |
| 3 years | +44.8% | +77.9% | −33.1 pts | −50.3 pts |
| Since launch | +715.8% | +804.4% | −88.5 pts | −958.1 pts |

## Every published field

| Field | Value | Source |
| --- | --- | --- |
| Theme | Biotech and genomics | ETFIQ, editorial |
| Launched | Jan 4, 2010 | ETFIQ |
| Already in the S&P 500, by weight | 60.7% | ETFIQ |
| Active share vs the S&P 500 | 99.0% | ETFIQ |
| Already in the Nasdaq-100, by weight | 48.4% | ETFIQ |
| Active share vs the Nasdaq-100 | 97.4% | ETFIQ |
| Top ten holdings weight | 72.0% | ETFIQ |
| Holdings | 24 | ETFIQ |
| Holdings as of | Sep 10, 2026 | the issuer’s daily file |
| Top holdings | Amgen Inc 14.3%, Gilead Sciences Inc 13.0%, Vertex Pharmaceuticals Inc 8.4%, Regeneron Pharmaceuticals Inc 7.0%, Moderna Inc 5.8%, Natera Inc 5.2%, Iqvia Holdings Inc 5.1%, Revolution Medicines Inc 5.1%, Argenx Se 4.7%, Illumina Inc 3.2% | ETFIQ |
| Net assets | $396m | SEC filing, whole fund, as filed for Jun 30, 2026 |
| Below its all-time high | −6.0% | ETFIQ |
| Expense ratio | 0.35% | 485BPOS XBRL, Jan 27, 2026 |
| Fee for the part that differs from the S&P 500, active expense ratio | 0.35% | ETFIQ |
| Closest funds by holdings overlap | IBBQ 53%, FBT 44%, PBE 43%, BMED 35%, HELX 25% | ETFIQ |

## Questions

### How much of BBH is in S&P 500 companies?

By its holdings published by its issuer for Sep 10, 2026, 61% of BBH by weight is stocks the S&P 500 already holds. Its active share against the index is 99%, so that share is the part doing something different.

### What does BBH hold?

24 positions as published by its issuer for Sep 10, 2026, with the top ten at 72% of the fund. The largest are Amgen Inc at 14.3%, Gilead Sciences Inc at 13.0%, Vertex Pharmaceuticals Inc at 8.4%.

### Has BBH beaten the S&P 500?

Over the year to Sep 11, 2026 BBH returned +36.1% with distributions reinvested, against +17.5% for the S&P 500, so it finished ahead of the index by 18.6 points.

### What does BBH cost?

The prospectus expense ratio is 0.35% a year. Because 99% of the fund differs from the S&P 500, the fee on that differing part works out at 0.35%.


## Cite this page

ETFIQ, BBH, data as of Sep 11, 2026. https://etfiq.com/funds/BBH
Free to use with attribution; the underlying files are at https://etfiq.com/data/.

HTML: https://etfiq.com/funds/BBH  ·  JSON: https://etfiq.com/funds/BBH.json